Physician profile
Robert Calvin Masterson
NPI 1053358853
$2,637.50
in general payments reported to CMS, 2019-2025
30 companies · $538 in 2025
The $538 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $312 · 2021: $360 · 2022: $441 · 2023: $387 · 2024: $341 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $605.06 | 2019-2025 | Wegovy, Saxenda, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $480.45 | 2020-2025 | Breztri, Farxiga |
| Idorsia Pharmaceuticals US INC | $165.92 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $131.64 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Astellas Pharma US INC | $111.05 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.89 | 2021-2025 | Jardiance |
| Amgen INC. | $95.77 | 2019-2020 | |
| Glaxosmithkline, LLC. | $81.93 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.01 | 2021-2022 | |
| Abbvie INC. | $77.53 | 2023-2025 | |
| Abbott Laboratories | $72.15 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $69.02 | 2022 | |
| Pfizer INC. | $67.10 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $54.57 | 2019-2020 | |
| Horizon Therapeutics Plc | $48.06 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $42.89 | 2021-2024 | Zepbound, Jardiance, Mounjaro |
| Stryker Corporation | $42.27 | 2025 | Clottriever Bold Catheter |
| Biohaven Pharmaceutical Holding Company LTD. | $41.15 | 2022 | |
| Eisai INC. | $40.57 | 2020 | |
| Genentech USA, INC. | $39.02 | 2019 | |
| Sanofi Pasteur INC. | $27.67 | 2025 | |
| Janssen Pharmaceuticals, INC | $26.17 | 2022 | |
| Inspire Medical Systems, INC. | $22.56 | 2025 | Inspire |
| Mylan Specialty L.P. | $22.41 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $22.19 | 2025 | Voquezna |
| Exact Sciences Corporation | $16.92 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $15.48 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.87 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.49 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Masterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.